HEPA: Hepion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on HEPA: Hepion Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.13
Enterprise Value ($M) 3.43
Book Value ($M) -0.41
Book Value / Share -0.06
Price / Book -2.78
NCAV ($M) -0.59
NCAV / Share -0.09
Price / NCAV -1.91

Profitability (mra)
Return on Invested Capital (ROIC) -12.50
Return on Assets (ROA) -1.25
Return on Equity (ROE) -3.12

Liquidity (mrq)
Quick Ratio 1.30
Current Ratio 1.30

Balance Sheet (mrq) ($M)
Current Assets 3.53
Assets 3.72
Liabilities 4.12
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G S.H.N. Financial Investments Ltd.
01-24 13G Bigger Capital Fund L P
11-14 13G/A Armistice Capital, Llc 4.99 -27.14

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-13 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-06-25 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A
2024-05-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 o TRANSITION REPORT PURSUANT TO
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 O

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 2,633,372 7,526,768 34.99
2025-02-03 1,034,721 7,027,001 14.72
2025-01-31 2,079,444 6,202,420 33.53
2025-01-30 2,340,128 8,013,381 29.20

(click for more detail)

Similar Companies
GRCE – Grace Therapeutics, Inc. GTBP – GT Biopharma, Inc.
GYRE – Gyre Therapeutics, Inc. HOOK – HOOKIPA Pharma Inc.
HOTH – Hoth Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io